Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Molecular Cancer Open Access 21 May 2024
-
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Communications Medicine Open Access 16 May 2024
-
WWP1 E3 ligase at the crossroads of health and disease
Cell Death & Disease Open Access 21 December 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. The PROTAC gold rush. Nat Biotechnol 40, 12–16 (2022). https://doi.org/10.1038/s41587-021-01173-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01173-2
This article is cited by
-
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Molecular Cancer (2024)
-
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Communications Medicine (2024)
-
The glue degraders
Nature Biotechnology (2024)
-
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Molecular Cancer (2023)
-
Strategies to therapeutically modulate cytokine action
Nature Reviews Drug Discovery (2023)